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5-FU based chemotherapy is the most common first line regimen used for metastatic colorectal
cancer (mCRC). Identification of predictive markers of response to chemotherapy is a challeng-
ing approach for drug selection. The present study analyzes the predictive role of 5-FU degra-
dation rate (5-FUDR) and genetic polymorphisms (MTHFR, TSER, DPYD) on survival.
Materials and Methods
Genetic polymorphisms of MTHFR, TSER and DPYD, and the 5-FUDR of homogenous
patients with mCRC were retrospectively studied. Genetic markers and the 5-FUDR were
correlated with clinical outcome.
Results
133 patients affected by mCRC, treated with fluoropyrimidine-based chemotherapy from
2009 to 2014, were evaluated. Patients were classified into three metabolic classes,
according to normal distribution of 5-FUDR in more than 1000 patients, as previously pub-
lished: poor-metabolizer (PM) with 5-FU-DR 0,85 ng/ml/106 cells/min (8 pts); normal
metabolizer with 0,85 < 5-FU-DR < 2,2 ng/ml/106 cells/min (119 pts); ultra-rapid metaboli-
zer (UM) with 5-FU-DR  2,2 ng/ml/106 cells/min (6 pts). PM and UM groups showed a lon-
ger PFS respect to normal metabolizer group (14.5 and 11 months respectively vs 8
months; p = 0.029). A higher G3-4 toxicity rate was observed in PM and UM, respect to nor-
mal metabolizer (50% in both PM and UM vs 18%; p = 0.019). No significant associations
between genes polymorphisms and outcomes or toxicities were observed.
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Conclusion
5-FUDR seems to be significantly involved in predicting survival of patients who underwent
5-FU based CHT for mCRC. Although our findings require confirmation in large prospective
studies, they reinforce the concept that individual genetic variation may allow personalized
selection of chemotherapy to optimize clinical outcomes.
Introduction
Colorectal cancer (CRC) is the second highest cause of cancer death inWestern countries. The
combinations of fluoropyrimidine with oxapliplatin or irinotecan and biological agents are the
most common first line chemotherapy regimens used for mCRC. [1–4]
5-Fluorouracil is an antimetabolite of the pyrimidine analogue type, that inhibits DNA and
RNA synthesis, with its activemetabolites, resulting from anabolism of about 1–2% of the drug.
5-FU active metabolites form an inactive ternary complex with thymidylate synthase (TS) and
5–10-methylenetetrahydrofolate (MTHF). TS optimal inhibition requires an elevated level of
MTHF, regulated by the methylenetetrahydrofolate reductase (MTHFR). [5] As a consequence,
polymorphisms in TS enhancing region (TSER) andMTHFR gene are presumed to be determi-
nants for 5-FU clinical response, even if their clinical utility is still controversial. [6–14]
Dihydropyrimidine dehydrogenase (DPD) polymorphically expressed enzyme, encoded by
DPD gene (DPYD) play a crucial role in the pharmacology of fluoropyrimidines, as it inactivates
up to 85% of 5-FU to 5,6-dihydro-5-fluorouracil. [15, 16] Genetic polymorphism in DPYD has
shown to be potentially responsible for lethal toxicity after 5FU-based chemotherapy. [17, 18]
Knowledge of the clinical impact of gene polymorphisms involved in the pharmacokinetics
and pharmacodynamics of fluoropyrimidinesmay provide opportunities for patient-tailored
chemotherapy, resulting in decreased incidence of severe side effects, reduced numbers of
treatment delays or discontinuations, and possibly increased survival probability.
In a previous study high-performance liquid chromatography (HPLC) was used to identify
an index of DPD metabolic activity, measuring uracil/dihydrouracil (U/UH2) ratio in plasma.
[19] In 2009 we proposed the determination of 5-FU degradation rate (5-FU-DR) by intact
peripheral bloodmonocuclear cells (PBMC) as a useful pre-screening test to evaluate drug tox-
icity. [20] Furthermore, a genotype-phenotype correlation in 5-FUmetabolismwas demon-
strated, through an association analysis betweenDPYD single nucleotide polymorphisms
(SNPs) and 5-FUDR. [21] Finally, we analysed the effects of the individual 5-FUDR on 5-FU
toxicity in a population of 433 CRC patients. We found that both the poormetabolizer (PM)
subjects, defined by a 5-FUDR 5th centile, and the ultra-rapid metabolizer (UM) patients,
defined by a 5-FUDR 95th centile, are at higher risk to develop G3-4 toxicity, with an OR of
3.47 and 3.34, respectively, compared to normal metabolizers (5th< 5FUDR< 95th centiles).
[22]
In the present study the Authors aim is to evaluate the influence of genetic polymorphisms
of the genes involved in 5-FUmetabolism and the of 5-FUDR on progression free survival in a
population of metastatic colorectal cancer patients.
Materials and Methods
Patients selection
From 2009 to 2014 patients with a histologically confirmedmetastatic adenocarcinoma of the
colon and rectum undergoing fluoropyrimidine-basedchemotherapy at the Sant’Andrea
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Hospital of Rome, were enrolled in this retrospective study. Each patient records were de-iden-
tified and analyzed anonymously.
The inclusions criteria were: patients with measurable disease, adequate organ function and
performance status grade 0, 1 or 2 as defined by the Eastern CooperativeOncologyGroup;
patients who undergone 5-FU and Capecitabine based chemotherapy (FOLFOX, XELOX,
FOLFIRI and Capecitabinemonotherapy) alone or in combination with biological agents;
patients who undergone pre-treatment assay of 5-FUDR and characterization of polymor-
phisms of TSER,MTHFR and DPYD genes.
The exclusion criteria were: relevant diseases within 6 months (i.e.: myocardial infarction,
lung fibrosis, etc); 5FU based chemotherapy in the past.
The study was conducted in accordance with the Declaration of Helsinki and the protocol
was approved by the institutional ethic committee.
Genotyping
Germinal polymorphisms were analyzed. Genomic DNA was isolated from peripheral blood
using the X-tractor Gene system (Corbett Life Science, Australia). The splice-site polymor-
phism, IVS14+1G>A in theDPYD gene, C677T and A1298C SNPs in MTHFR gene were ana-
lyzed using the commercial kit for fluoropyrimidine response (Diatech, Jesi, Italy) according to
manufacturer’s protocol. Briefly, region covering the SNP of interest was amplified by PCR,
using specific primers, and then sequenced, using the Pyrosequencer PyroMark ID system
(Biotage AB and Biosystems, Uppsala, Sweden). The variable number of tandem repeats
(VNTR; 2R or 3R) in TSER was determined by PCR according to manufacturer’s protocol
(fluoropyrimidine response—Diatech, Jesi, Italy) and visualized onto 2,2% agarose gel.
Determination of the individual 5FU degradation rate. The test was performed using a
HPLC-MS/MS instrument including an Agilent 1100 chromatographic system coupled to an
API 3200 triple quadrupole (ABSCIEX, Framingham, MA, USA). [15] Briefly, freshly prepared
peripheral bloodmononuclear cells (2.5–3.5 x 106 cells) are incubate at 37°C, with shaking,
with a known amount of 5-FU. Cells aliquots are drawn at time 0, 1 h and 2 h, lysed and centri-
fuged and the concentration of 5-FU in the supernatants is quantified by HPLC-MS/MS. The
5-FUDR is expressed as ng 5-FU/ml/106 cells/min.
Chemotherapy response, toxicity and survival
Chemotherapy cycles were administered every 2 or 3 weeks until disease progression or the
development of unacceptable toxicity. We focused in patients undergoing chemotherapy con-
sisting of FOLFOX, FOLFIRI, XELOX and Capecitabine with or without BEVACIZUMAB or
CETUXIMAB.
Radiological response was assessed with RECIST Criteria. All toxicity was graded according
to the National Cancer Institute Common Toxicity Criteria and toxicity assessments per-
formed at day 1 of each cycle until the end of treatment. Patients were also analyzed according
to disease control rate (complete response, partial response and stable disease) and progressive
disease. Progression-free survival (PFS) was defined as the time from treatment beginning until
the first documented tumour progression or death from any cause. Overall survival (OS) was
defined as the time from treatment beginning to death from any cause.
Data analysis and statistics
Patients' data were shown as mean ± SD or median (range) as appropriate. Metabolic classes
were determined according to the degradation rates as reported in our previous published arti-
cle. [22] Box plots of time to progression according the metabolic classes and toxicity were
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used to show variability among groups. Chi-square test was calculated according to investi-
gated groups.
Patients were also analyzed according to disease control rate (complete response, partial
response and stable disease) and progressive disease.
Kaplan-Meier curveswere generated according the metabolic classes. Coxmultivariate anal-
ysis was calculated.
All tests were two-sided, and differences were considered significant at P< 0.05.
All statistics were calculated using R-Package (version 3.1).
Results
133 metastatic colorectal cancer patients were evaluated in this study. Clinical characteristics
and genotype frequencies for MTHFR677/1298, TSER and DPYD are reported in Table 1.
MTHFR677,MTHFR1298 and TSER resulted mutated (heterozygous or homozygous
mutated) in 72.2%, 48.2% and 73% of cases, respectively, while DPYD was heterozigously
mutated in only one case (0.8%).
Table 1. Baseline characteristics of mCRC patients (n = 133 patients).




AGE 68 years (32–86)
TYPE OF TREATMENT
CAPECITABINE BASED 20 15.0%
MONOTHERAPY 19 95%
COMBINATION THERAPY 1 5%
5-FU BASED 113 85.0%
FOLFIRI +/- TARGET AGENT 60 53.1%
















5-FU-DR (NG/ML/MIN) 1.610 (0.460–2.570)
 0.85 8 6%
>0.85, <2.2 119 89%
 2.2 6 5%
doi:10.1371/journal.pone.0163105.t001
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The median 5-FUDR value in the overall population was 1.610 (0.460–2.570) ng/ml/106
cells/min.
Overall, 5-FUDR was 0.85 ng/mL/min in 8 patients (6% of the cases as poormetabolizers,
PM) between 0.85 and 2.2 ng/mL/min in 119 patients (89% of the cases as normal metaboli-
zers) and 2.2 ng/mL/min in 6 patients (5% of the cases as ultra-rapid metabolizers, UM).
Survival
Information on clinical response to treatment was available for all the 133 patients studied.
The median PFS was 8 months, while the median OS was 28 months. No significant associa-
tions at the univariate and multivariate analysis were observedbetweenOS and genetic poly-
morphisms or metabolic classes.
Patients poor and ultra-rapid metabolizers showed a better median PFS compared to those
with normal 5-FUDR (14.5 and 11 vs. 8 months respectively, p = 0.029). (Fig 1; Table 2)
PFS of patients with normal 5-FU-DR was lower than PFS of patients with altered 5-FUDR
(8 vs 11 months, p = 0.03). (Fig 2)
The boxplot of time to progression according to the metabolic classes is shown in Fig 3. The
median time to progression was higher for patient with a poor than normal and ultra-metaboli-
zer (14.5 vs. 7.5 and 10.5 months respectively).
Fig 1. PFS according to the metabolic classes (p = 0.0029).
doi:10.1371/journal.pone.0163105.g001
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Toxicity
Severe toxicities (grade 3 or 4 toxicity) were encountered in 28 patients (21%) and were found
to be significantly associated (p = 0.019) with a 5-FUDR below the 5th centile (PM) or above
the 95th centile (UM). In particular, the severe toxicity rate was 50% in PM and UM while it
was 17.6% in the remaining patients.
In the investigated cohort, 37 patients received a reduced chemotherapy dose. 7 PM subjects
received a reduced dose (88.5% of the cases); while in normal and UM groups 23.5% and 33.3%
of patients received a reduced dose of 5-FU (p = 0.0004). (Table 3)
Discussion
The aims of this study was to investigate the efficacy of 5-FU degradation rate and genetic poly-
morphisms (MTHFR,DPYD, and TSER) as prognostic and predictive parameter for progres-
sion free survival.
So far, some studies have investigated the MTHFR,DPYD and TSER genotypes as predic-
tors of toxicity to 5-FU-based chemotherapy. [17, 18, 23–33] The most consistent evidence
concerns the DPYD gene, demonstrating an association between severe toxicity and the pres-
ence of the polymorphism. [17, 18, 29–33] Interestingly, a case-cohort analysis on the patients
enrolled in the phase III CAIRO2 trial showed that DPYD polymorphisms are related to grade
3–4 toxicities, with a trend toward increased overall survival. [17] Moreover, a recent published
study, performed on 2038 patients, demonstrated that with a pharmacokinetically guided dose
adjustments of 5-FU the incidence and severity of adverse events were significantly reduced,
with drug related death decrease from 10% to 0% and G3-4 toxicities risk reduced from 73% to
28%. Unfortunately, the authors did not present any results about clinical outcomes, despite
50% dose reduction. [18] Recently, an increasing interest has been shown in identifying
Table 2. Progression free survival (PFS) acconding to gene polymorphisms and 5-FU degradation rate (5-FU-DR).
MEDIAN PFS (months) PFS RANGE (months) P VALUE
ALL PATIENTS 8.0 2.0–33.0
DPYD
GG 8.0 2.0–33.0












TT 9.0 3.0–28.0 NS
5-FU-DR (NG/ML/MIN)
 0.85 14.5 5.0–28.0
> 0.85, < 2.2 8.0 2.0–33.0
 2.2 11.0 8.0–19.0 0.029
doi:10.1371/journal.pone.0163105.t002
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prognostic and predictive factor through gene polymorphisms’analysis. Actually, several stud-
ies have shown an association between response to treatment and polymorphisms in genes
encoding enzymes involved in 5-fluorouracil metabolism, but none of these is considered a
prognostic factor in clinical practice. [34–46]
In this study, the distribution of MTHFR677/1298, TSER and DPYD polymorphisms was
similar to those described in other Caucasian populations. [47, 48] In our series only one
patient presented mutation for DPYD so we could not adequately evaluate the association to
efficacy and safety. The effect of genetic polymorphisms of DPYD, TSER,MTHFR and degra-
dation rate of 5-FU on survival was studied. No significant differences in terms of PFS and OS
related with MTHFR677/1298, TSER and DPYD polymorphisms were found. These results
concur with several other studies that used FOLFOX or FOLFIRI [49–51], but not with tree
others that used 5-FUmonotherapy and reported better response for patients with the mutated
MTHFR677/1298 genotypes [52–54].
Interesting associations with outcomes were found when 5-FUDR was studied. Patients
with a low 5-FUDR ( 0.85 ng/ml/min) and high 5-FUDR ( 2,2 ng/ml/min) presented a sig-
nificant increase in PFS at the univariate analysis, compared to patients with a normal
5-FUDR. Instead we didn’t find any associations between 5-FUDR and OS, but it could depend
that patients lost at follow up reduced the sample size for the analysis of OS.
Fig 2. PFS of patients with normal and altered 5-FU-DR (p = 0.03).
doi:10.1371/journal.pone.0163105.g002
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Fig 3. The boxplot of time to progression according to the 5FUDR-based metabolic classes.
doi:10.1371/journal.pone.0163105.g003
Table 3. Dose reduction and toxicity according to gene polymorphisms and 5-FU-DR.
TOTAL GRADE 0–2 GRADE 3–4 P VALUE DOSE REDUCTION
N % N % N % N % P value
GENDER
MALE 71 53.4% 61 85.9% 10 14.1% 19 27.8%
FAMALE 62 46.6% 44 71% 18 29% NS 17 27.4% NS
DPYD
GG 132 99.2% 104 78.8% 28 21.2% 36 27.3%
GA 1 0.8% 1 100% 0 0% NS 1 100% NS
TSER
2R/2R 36 27.1% 28 77.8% 8 22.2% 11 30.6%
2R/3R 57 42.9% 45 78.9% 12 21% 17 29.8%
3R/3R 40 30.1% 32 80% 8 20% NS 9 22.5% NS
MTHFR1298
AA 69 51.9% 52 75.4% 17 24.6% 22 31.9%
AC 55 41.4% 45 81.8% 10 18.2% 10 18.2%
CC 9 6.8% 8 88.9% 1 11.1% NS 5 55.6% NS
MTHFR677
CC 37 27.8% 32 86.5% 5 13.5% 9 24.3%
CT 65 48.9% 49 75.4% 16 24.6% 17 26.2%
TT 31 23.3% 24 77.4% 7 22.6% NS 11 35.5% NS
5-FU-DR (NG/ML/MIN)
 0.85 8 6% 4 50% 4 50% 7 87.5%
>0.85, <2.2 119 89% 98 82.4% 21 17.6% 28 23.5%
 2.2 6 5% 3 50% 3 50% 0.019 2 33.3% 0.0004
doi:10.1371/journal.pone.0163105.t003
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Moreover, poormetabolizing patients presented a better progression free survival, even
though 7 of 8 patients received a reduced dose of 5-FU. This result, enlightens the remarkable
finding that probably the pharmacogenetic of these patients allows a longer and effective per-
sistence of 5-FU during treatment.
Surprisingly, a better outcome and higher toxicity grade (3 patients of 6; 50%) was observed
also in UM group. So far a relationship between increased toxicity and/or better outcomes with
fast drugmetabolismwas not reported in literature. The faster 5-FU consumption, expressed
with a higher value of 5-FUDR, should be related to an increasedDPD activity, with 5-FU inac-
tive metabolites raise, or with an augmented activity of enzymes involved in 5-FU active metab-
olites production, i.e. orotate phosphoribosyltransferase (ORPT), thymidine phosphorylase
(TP) and uridine phosphorilase (UP). [55] In this regard, literature data showed that 5-FU sen-
sitivity is associated with OPRT gene polymorphisms and OPRT/DPD activity ratio. [56–58]
This finding leads to the hypothesis that UM show better PFS and higher rate of severe toxici-
ties, due to the increased amount of 5-FU active metabolites. (Fig 4)
The present study focused on the importance of degradation rate of 5-FU and genetic poly-
morphisms in predicting toxicity and survival of metastatic colorectal cancer patients who under-
went 5-FU based chemotherapy. The Authors demonstrated the relevance of 5-FU degradation
rate analysis on avoidance of adverse event occurrence, and its role in predicting survival.
Further prospective studies are needed in order to validate and verify these novel and rele-
vant findings. OPRT, UP and TP gene analysis and the dosage of 5-FUmetabolites are required
to better understand pharmacokineticsmechanisms involved.
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